JUUL and other e-cigarette makers have never received approval from the U.S. Food and Drug Administration (FDA) to market themselves as less risky than smoking. Nevertheless, JUUL initially pitched its products as a “safer alternative” to cigarettes.

Over time, the company’s claims were challenged by federal health authorities and a series of lawsuitsTheir deceptive marketing rings especially untrue in light of the COVID-19 pandemic.


According to a spokesperson from the FDA:

People with underlying health issues, such as heart or lung problems, may have increased risk for serious complications from Covid-19. This includes people who smoke and/or vape tobacco or nicotine-containing products…E-cigarettes can damage lung cells.”

While the FDA declined to comment further, many health experts have speculated that vaping is leading to increased COVID-19 hospitalizations among younger patients. The director of the National Institute on Drug Abuse affirmed that Coronavirus “could be an especially serious threat” to those who vape.


This direct language from the FDA and healthcare professionals further jeopardizes JUUL’s marketing claims and strengthens new and existing lawsuits against the company. As more outbreaks and evidence emerge, we can see very clearly that vaping can lead to health problems.

Not only were JUUL and other e-cigarette companies linked to an EVALI (e-cigarette, or vaping, product use-associated lung injury) outbreak that peaked in September 2019, but these manufacturers are also being tied to COVID-19 by several reputable sources.

If you’ve been affected by EVALI, COVID-19 complications, or even addiction, please do not hesitate to contact Frantz Law Group, APLC for legal help.

Call us at (855) 735-5945 today or reach out online to schedule your free consultation.

**Please note that COVID-19 is a rapidly evolving situation. For the most accurate and up-to-date information on the disease, please consult the Centers for Disease Control and Prevention (CDC) or the World Health Organization (WHO).